Connect your AI

Arrowhead Research ARWR SG&A

SG&A at other companies

Ionis PharmaceuticalsIONS

$150.36M+97.2%

BridgeBio PharmaBBIO

$163.9M+54.1%

Madrigal Pharmaceuticals, Inc.MDGL

$268.52M+60.0%

AbbVieABBV

$3.58B+8.7%

RevvityRVTY

$253.88M+1.7%

ALN

Alnylam PharmaceuticalsALNY

——

Other financials

Income statement

Revenue$73.7M-86.4%

Operating income-$141.3M-137%

Net income-$132.7M-136%

EPS (diluted)-$0.93-134%

Balance sheet

Cash & equivalents$188.5M+1.5%

Total debt$107.9M-5.6%

Total equity$614.0M-10.1%

Total assets$2.3B+44.2%

Cash flow

Operating cash flow$84.4M-81.6%

CapEx$2.6M-51.6%

Free cash flow$81.9M-82.0%

Valuation

Market cap$11.52B+402%

Enterprise value$11.44B+418%

P/S18.5×+14.3×

Profitability

Operating margin-35.7%+63.6pp

Net margin-48.4%+240pp

FCF margin1.8%+0.9pp

Returns & leverage

Return on equity-46.4%+341pp

Debt / equity0.2×0.0×

Current ratio6.2×+1.1×

Where this comes from

Reported directly by Arrowhead Research in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The official record: Arrowhead Research’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arrowhead Research's sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Arrowhead Research's SG&A?: Arrowhead Research (ARWR) reported SG&A of $41.74M in Q1 2026.